Applied DNA Sciences Seeks NYSDOH Approval for Novel H5 Bird Flu Diagnostic Test
核心洞察
Applied DNA Clinical Labs (搜索) has submitted a validation package to the New York State Department of Health for approval of its PCR-based H5 bird flu (搜索) diagnostic test, capable of detecting and differentiating between pan-influenza A (搜索) and H5 subtypes.
The test development was initiated in January 2025 amid growing concerns about H5N1 (搜索) spread in dairy cows, poultry, and several human cases in U.S. agricultural workers, aligning with CDC (搜索) recommendations for rapid influenza subtyping.
If approved, the Linea Avian Influenza H5 Dx (搜索) assay would be available to physicians nationwide through ADCL (搜索)'s CLIA-certified laboratory, expanding the company's diagnostic testing portfolio that includes mpox and pharmacogenetic testing.
Applied DNA Clinical Labs (搜索) (ADCL (搜索)), a wholly-owned subsidiary of Applied DNA Sciences (搜索) (NASDAQ: APDN), has submitted a validation package to the New York State Department of Health (NYSDOH) seeking approval for a laboratory-developed test (LDT) designed to detect and subtype the H5 bird flu (搜索) virus. The PCR-based diagnostic assay, named Linea™ Avian Influenza H5 Dx (AIH5 Dx (搜索)), can distinguish between pan-influenza A (搜索) and the highly pathogenic avian influenza (搜索) (H5N1 (搜索)) that has raised public health concerns across the United States.
The development of this diagnostic test comes amid escalating concerns regarding the spread of H5 bird flu (搜索) in U.S. dairy cattle and poultry operations, along with several confirmed human infections among agricultural workers. The Centers for Disease Control and Prevention (搜索) (CDC (搜索)) has issued health advisories recommending rapid subtyping of all influenza A (搜索)-positive specimens from hospitalized patients.
"This past December, scientists at Scripps Research (搜索) identified a mutation in H5 bird flu (搜索) that could turn the virus from one that is currently not well-equipped to infect people into one that is much more capable of doing so," stated Dr. James A. Hayward, CEO of Applied DNA. "Last month, the Centers for Disease Control and Prevention (搜索) reported that human H5 bird flu infections are potentially underestimated in the U.S. Against this backdrop, our development of AIH5 Dx (搜索) leverages our demonstrated ability to rapidly develop and gain regulatory approval for LDTs targeting emergent health crises."
Test Capabilities and Deployment Plan
The Linea™ AIH5 Dx (搜索) assay is described as a highly sensitive, multi-target diagnostic test capable of detecting and discriminating between pan-influenza A (搜索) and H5 bird flu (搜索). If approved by NYSDOH, ADCL (搜索) plans to launch a testing service that would accept samples from all U.S. states that recognize New York's CLEP/CLIA certification.
Patient samples would be processed at ADCL (搜索)'s NYSDOH CLEP-permitted, CLIA-certified laboratory, which is currently permitted for virology and molecular genetics testing. The H5 bird flu (搜索) test would join ADCL's existing diagnostic testing menu, which includes LDTs for mpox Clade I and II, SARS-CoV-2, and pharmacogenetic testing (TR8 PGx).
Scientific Context and Public Health Implications
Recent scientific findings have heightened concerns about the potential for H5N1 (搜索) to adapt for human-to-human transmission. A study published in Science by researchers at Scripps Research (搜索) identified a single mutation that could switch the virus's receptor specificity to human cells, potentially increasing transmissibility among people.
Additionally, CDC (搜索) research published in the Morbidity and Mortality Weekly Report suggests that human H5 bird flu (搜索) infections may be underestimated in the United States. A seroprevalence study among bovine veterinary practitioners found evidence of previous exposure to the virus, indicating that more human infections may have occurred than officially reported.
Regulatory Timeline and Commercial Outlook
The timeline for NYSDOH's review of the validation package remains uncertain, as does the ultimate approval decision. Applied DNA Sciences (搜索) has emphasized that the company is prepared to rapidly deploy the testing service using existing laboratory infrastructure and workflows if approval is granted.
The Linea™ AIH5 Dx (搜索) assay was developed and validated by ADCL (搜索) as a high-complexity test intended for clinical purposes. The test would enable physicians to order diagnostic testing for patients suspected of H5 bird flu (搜索) infection, potentially improving surveillance and clinical management of cases.
Applied DNA Sciences (搜索), headquartered in Stony Brook, NY, specializes in PCR-based DNA technologies with applications in both molecular diagnostics and the production of synthetic DNA for therapeutic applications. The company has previously demonstrated its ability to rapidly develop diagnostic tests in response to emerging infectious disease threats, including tests for mpox and SARS-CoV-2.
Market and Financial Considerations
While the potential market size for H5 bird flu (搜索) testing remains uncertain and dependent on the future trajectory of the outbreak, Applied DNA Sciences (搜索) is positioning itself to respond to what could become a significant public health need. The company has a history of net losses, and the financial impact of this new diagnostic test will depend on approval timelines, the evolution of the H5N1 (搜索) situation, and market adoption.
The company has not provided specific revenue projections for the test, and investors are cautioned that actual results could differ from expectations due to various factors, including the unpredictable course of the H5 bird flu (搜索) outbreak and uncertain demand for testing services.